Research Engineer in Microbiology – 18 months

An 18-month Research Engineer position is available in a collaborative drug development project between BioVersys AG (Basel, Switzerland) and the Center for Infection and Immunity of Lille at Institut Pasteur de Lille (France). 

BioVersys AG is a highly innovative biotechnology company at the forefront of the fight against AMR and is leading a partnership with GlaxoSmithKline (Madrid), the Institut Pasteur de Lille and the University of Lille to develop a novel anti-tuberculosis drug: BVL-GSK098. Tuberculosis (TB) is the main cause of death by an infectious disease worldwide. The challenge to treat TB is further complicated by the growing threat of antibiotic resistance, making the need for new drugs ever more pressing. 

BVL-GSK098 was designed to boost the activity of the anti-TB drug ethionamide and overcome existing resistance to ethionamide, including in difficult-to-treat multi-drug resistant (MDR) TB. Its development is partly supported by the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) through a grant of €6.92 million ( Through these and earlier efforts, BVL-GSK098 has completed pre-clinical safety and toxicity assessments and is entering clinical evaluation. 

BioVersys AG is recruiting a collaborator to perform laboratory-based microbiology, informed by Mycobacterium tuberculosis genetics to support ongoing clinical development of BVL-GSK098. The position is based at the Center for Infection and Immunity of Lille, Institut Pasteur de Lille (France) in the team of Alain Baulard, with tight interaction with the BioVersys AG team in Basel, Switzerland. 

You will be in charge of: 

  1. designing, planning and executing microbiological investigations of BVL- GSK098 in a high containment laboratory setting (BSL-3);
  2. analyzing, synthesizing and communicating your findings to the team;
  3. collaboratively writing reports that will inform clinical development.

You are: 

  1. An independent scientist with a PhD in microbiology, molecular biology or equivalent, capable of working with little supervision.
  2. Experienced in working with pathogens, preferably M. tuberculosis in a BSL-3 setting. Experience of mammalian cell culture and infection models is a plus.
  3. A good communicator with an excellent command of English (both written and spoken) undaunted by the prospect of working in a geographically dispersed team.
  4. Excited to be part of a dynamic drug development program, bringing new therapies to people in need.

Starting date October 1st, 2020 or date to be agreed upon. 

Contact Applicant should send a CV and a cover letter including contact information of two references to Alain Baulard, and Alina Lundin, 

BioVersys AG is a privately owned Swiss pharmaceutical company focusing on research and development of small molecules acting on novel bacterial targets with applications in Anti-Microbial Resistance (AMR) and targeted microbiome modulation. With the company’s award-winning TRIC technology we can overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria, towards the identification of new treatment options in the antimicrobial and microbiome fields. By this means BioVersys addresses the high unmet medical need for new treatments against life threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced R&D programs are in preclinical development for nosocomial infections (hospital infections), and Tuberculosis in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille. In 2020 BioVersys plans to launch its first Phase I clinical trials. Please visit
Partager cet Article
Avez-vous aimé cet article ?
0 0

Laisser une réponse

Votre adresse e-mail ne sera pas publiée. Les champs requis sont marqués *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>